Phaseline

Targets › TPBG

TPBG (Trophoblast glycoprotein): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 3 Phase 1; Oncology; next expected readout Mar 2027.

May function as an inhibitor of Wnt/beta-catenin signaling by indirectly interacting with LRP6 and blocking Wnt3a-dependent LRP6 internalization. (UniProt, Q13641)

Open in Phaseline: the race on TPBG, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NeoTX TherapeuticsNaptumomab estafenatox
Trophoblast glycoprotein other
TPBGPhase 1ER+ Breast CancerMar 2027
Qilu PharmaceuticalQLS5212
anti-trophoblast glycoprotein (TPBG) antibody-drug conjugate
TPBGPhase 1Solid Tumor CancerNov 2027
Salubris BiotherapeuticsJK06
Biparatopic anti-5T4 antibody
TPBGPhase 1Solid TumorApr 2028

Conditions

Solid Tumor (1) ER+ Breast Cancer (1) Solid Tumor Cancer (1)

Modalities

small molecule (2), antibody (1)

Companies

Salubris Biotherapeutics (1) NeoTX Therapeutics (1) Qilu Pharmaceutical (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.